Multiomics Market Size, Share, Trends and Forecast, 2026-2034
REPORT DETAILS
Multiomics Market Summary
Multiomics Market size was valued at USD 3.20 Billion in 2025. The multi-omics industry is anticipated to grow from USD 3.68 Billion in 2026 to USD 11.53 Billion by 2034, exhibiting a CAGR of 15.30% during the forecast period.
Market Statistics
Multiomics Market Key Takeaways
- North America held the largest share of the multiomics market in 2025, accounting for 38.0% of revenue. The region is growing because of strong research, more industry partnerships, and increasing cases of chronic diseases.
- Europe is expected to grow at the fastest CAGR of 14.9% during 2026–2034. Government help for genomics research and more healthcare research projects are helping the market grow.
- The Product & Service segment had the largest share of 76.0% in 2025. Large demand for instruments, consumables, and multiomics products is driving the segment.
- The Single-Cell Multi-Omics segment accounted for the largest revenue share of 52.0% in 2025. The market growth is being driven by the increasing application in cancer research, gene therapy and single-cell studies.
- The Metabolomics platform is projected to grow at the fastest CAGR of 14.8% from 2026 to 2034. This is due to its growing application in customized healthcare and drug discovery.
- The Genomics platform was the largest revenue contributor in 2025 with 32.0%. The segment’s growth being supported by advances in sequencing technology and declining sequencing costs.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
What Is Multiomics?
Multiomics uses data from genes, proteins, metabolites and cells to provide a more complete picture of biological processes. It looks at these different layers together rather than separately using omics technologies. This allows investigators to better understand diseases, discover treatment targets, improve diagnosis and support personalized healthcare research for better patient care.
How Multiomics Analysis Works
Multiomics starts with collecting biological samples. These samples include blood or tissue. For molecular profiling scientists analyze DNA, RNA, proteins, and metabolites. Advanced omics technologies generate data from each analysis. Then computational biology and bioinformatics tools integrate all datasets. Machine learning and artificial intelligence analyze the integrated data. This is critical to detect trends, biomarkers and disease related changes. To better understand diseases, researchers apply these findings. The results contribute to improve diagnosis, support drug discovery and guide personalized healthcare.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
Multiomics Market Drivers and Opportunities
Rising Adoption of Single-Cell and Spatial Multiomics
Technological advancements play an important role in driving the growth of the multiomics market. Single-cell multi-omics integrated with advanced technology such as AI and data analytics enable in-depth analysis of individual cells and provide insights into proteomics, metabolomics, genomics, & transcriptomics. These advances among players have formed strategic partnerships and collaborations to cater to the demand for single-cell multi-omics-based software. For instance, in July 2022, Sirona Dx Partnered with Scailyte for AI-driven software for single-cell analysis. This partnership aims to focus on applications within oncology and immunology.
Rising Research Funding and Pharmaceutical R&D Investment
Increased funding for research and development plays a significant role in driving the multiomics market. Various government agencies and market players invested to increase advancement in human health and disease. Industry academia collaboration focuses on the new technology development for multi-omics applications, paves the importance for personalized medicine in early disease diagnosis. For instance, in September 2023, the National Institutes of Health (NIH) funded USD 50.3 million for research on multi-omics research on human health and disease for five years.
Proteogenomics and Proteomics in Multiomics Research
Proteomics is an important part of multiomics because it focuses on proteins, which perform most functions inside cells. It is used for identification of proteins, functional biology studies, biomarker discovery, drug response monitoring and disease pathway analysis. The integration of proteomics with molecular profiling and computational biology provides more in depth understanding of disease development and treatment response. Data of the protein level provide information beyond that of the genome data alone and this is what makes the multiomics to be more beneficial for research and clinical use.
Multiomics in Precision Medicine and Precision Oncology
Multiomics is changing the way precision medicine is developed and used. By combining different types of biological data, it allows researchers and healthcare professionals to select more personalized treatments, group patients based on their disease profiles, predict disease risk, and improve precision oncology. It also plays an important role in precision healthcare and personalized medicine research. As research continues to grow, multiomics is becoming an important part of next-generation healthcare systems.
Multiomics Market Restraints and Challenges
High Instrument, Sequencing and Data-Analysis Costs
The higher investment in advanced technology, such as data analytics, artificial intelligence, machine learning, and others, due to the complexity of data integration, hinders the market's growth. High expenses may restrict innovation and impede the pace of technological advancement in the multi-omics industry, potentially hindering market demand in the coming years.
Multiomics Market Size, Scope and Growth Outlook
The multi-omics encompasses the integration of multiple omics disciplines (genomics, proteomics, metabolomics, and others) to analyze biological systems comprehensively. It enables holistic insights into complex biological phenomena, driving advancements in personalized medicine and precision agriculture. The multiomics market growth is driven by advancements in technology such as cloud-based and single-cell technology, increased investment in R&D, and rising demand for better diagnostic tests. For instance, in June 2021, SCIEX launched the OneOmics suite software and the Molecule Profiler app. OneOmics is a cloud-based platform that is used to analyze large-scale data sets of lipids, proteins, and metabolites. Also, it facilitates easy processing of research and analysis of large-scale data of multi-omics studies.
Furthermore, the rising chronic diseases such as diabetes, cancer, heart disease, and others facilitate the need for multi-omics software or solutions to understand complex molecular data. This increasing prevalence of chronic diseases drives the multiomics market during the forecast period. In January 2024, according to the Global Heart & Circulatory Diseases Factsheet Report, in 2021, approximately 200 million cases were registered for coronary heart disease (CHD), with 110 million men and 80 million women globally.
Moreover, increasing collaboration and partnership among key players such as Thermo Fisher Scientific, Lunaphore, & Bruker facilitates multiomics market growth. For instance, in April 2023, Bio-Techne & Lunaphore partnered to develop an automated same-slide spatial multi-omics solution. This collaboration aims to create advanced technology that enables the detection of protein and RNA biomarkers on the same slide and the understanding of disease mechanisms for improved therapeutics and diagnostics.
Multiomics vs. Single-Omics Approaches
| Feature | Multiomics | Single-Omics |
| Data Source | Uses multiple biological layers | Uses one type of biological data |
| Biological Insights | Gives a more complete understanding | Provides limited insights |
| Precision Medicine | Better supports personalized treatment | Offers moderate support |
| Biomarker Discovery | Supports identify biomarkers more effectively | Identifies fewer biomarkers |
| Complexity | More complex to perform and analyze | Simpler to perform and analyze |
Source: Polaris Market Research Analysis
Multiomics Market Drivers, Opportunities, Restraints and Challenges
- Advancements in single-cell multi-omics and AI are driving market growth.
- Rising research funding is accelerating multi-omics innovation and adoption.
- Growing demand for precision medicine is increasing the use of multi-omics technologies.
- Expanding applications in pharmaceutical and biotechnology research are helping market growth.
- High costs of advanced technologies and data integration are restraining market growth.
AI Impact on Multiomics Data Integration, Biomarker Discovery and Drug Research
- AI helps in analyzing multi-omics data by processing complex and voluminous datasets at a faster pace.
- AI helps in identifying biomarkers and disease patterns, which helps precision medicine.
- By improving target identification and research efficiency AI accelerates drug discovery.
- AI supports in automating data integration and interpretation. It reduces analysis time and improves accuracy.
Source: Polaris Market Research Analysis
Multiomics Market Segmentation by Product, Type, Platform, Technology, Application and End User
Multiomics Market Segment Analysis
| By Product & Service | By Type | By Platform | By Application | By Region |
|
|
|
|
|
Source: Polaris Market Research Analysis
Multiomics Market by Product and Service: Instruments, Consumables, Software and Services
The Product Segment Accounted for the Largest Market Share in 2025
The product segment held the largest revenue share in the multiomics market due to the rising prevalence of chronic diseases globally. Moreover, the growing adoption of single-cell multi-omics with the integration of advanced technology further boosts the segment’s growth in the multiomics market. For instance, in January 2025, BD and Hamilton collaborated to standardize single-cell multi-omics applications using robotics. This collaboration aims to enable greater standardization and reduce human error while conducting large-scale single-cell multi-omics experiments.
By Type Analysis
Single-Cell Multi-Omics Segment Accounted for the Largest Market Share in 2025
The single-cell multi-omics segment held the largest market share for the multiomics market in 2025 because of its use in various applications such as developmental biology, cancer biology, gene therapy, stem cell biology, and functional screening. Also, market players are introducing products integrated with AI, leading to a growing demand for single-cell multi-omics products. For example, in May 2023, Deepcell launched the AI-powered single-cell analysis REM-I platform.
Single-cell multi-omics technologies enable the simultaneous profiling of multiple molecular layers, such as the genome, epigenome, transcriptome, and proteome, within individual cells. This provides unprecedented opportunities to explore cellular diversity and heterogeneity by revealing regulatory connections between different omics layers.
The bulk multi-omics segment is projected to grow at a significant CAGR in the multiomics market during the projected period. This growth is primarily due to advantages such as the simplicity of the process, the ability to dissect large-scale samples, and cost-effectiveness. Moreover, expanding applications in personalized medicine and drug discovery also drive the segment’s growth in the multiomics market.
Multiomics Market by Platform: Genomics, Transcriptomics, Proteomics and Metabolomics
The Metabolomics Segment is Expected to Witness the Highest Growth
The metabolomics segment is projected to grow at the highest CAGR during the projected period, mainly driven by technological advancement in metabolomics platforms and expanding applications in personalized medicine and drug discovery. For instance, in November 2023, Panome Bio added unbiased proteomics to its proprietary metabolomics platform to deliver innovative multi-omics services.
The Genomics segment garnered the largest revenue share for the multiomics market in 2023. The advancements in genomic data analysis tools and decreasing costs of sequencing technologies drive the segment growth. Market players like Biomodal are introducing new products and solutions for new epigenetic and pedigree analysis. For instance, in April 2024, Biomodal (Cambridge Epigenetix) launched a multi-omics solution, which shows the combined power of genetic and epigenetic information from a single low-volume sample.
Data Standardization, Interoperability, Privacy and Skills Challenges
Despite the rapid growth of the multiomics market, there are some challenges. The high cost of technology can be prohibitive for some organizations. Integrating data from various sources can be complex. Many laboratories still do not have standardized workflows. Multiomics generates large volumes of data that require efficient storage and management solutions. The shortage of skilled professionals with bioinformatics expertise poses a challenge. Regulatory requirements and data privacy issues need to be addressed thoughtfully. These challenges may hinder the broader application of multiomics, even as interest in this field continues to grow.
Source: Polaris Market Research Analysis
Common Applications of Multiomics
| Use Case | Used In |
| Cancer biomarker discovery | Used in early cancer detection and treatment planning. |
| Precision medicine development | Used in developing personalized treatments. |
| Drug target identification | Used in finding new drug targets. |
| Rare disease research | Used in studying rare genetic disorders. |
| Clinical diagnostics | Used in improving disease diagnosis. |
| Immunology studies | Used in studying immune system responses. |
| Neurological disease research | Used in researching brain and nervous system disorders. |
| Microbiome analysis | Used in studying the role of microorganisms in health. |
| Agricultural biotechnology | Used in improving crop quality and disease resistance. |
| Personalized treatment planning | Used in selecting the most suitable treatment for patients. |
Source: Polaris Market Research Analysis
Multiomics Market Regional Analysis
The North American Region Registered the Largest Share of the Global Market in 2025
The North America multiomics market held the dominant share in 2025 owing to the presence of key players, collaborations among the industry & research community, and investments in the multi-omics applications. Further, the rising chronic diseases in the region also boost the multiomics market growth. For instance, as per the statistics published by the Canadian Cancer Society (CCS), in 2023, around 239,100 people were diagnosed with cancer in Canada, with a mortality of 20%. Also, the expansion of laboratories by leading players to cater to the demand for multi-omics drives the market in the region. For instance, in February 2024, Singleton, a single-cell multi-omics solutions provider, expanded its presence in Michigan, the US, with a new office and laboratories.
The Europe multiomics market will grow rapidly during the forecast period, owing to the growing government initiatives towards research projects on large-scale analysis, such as cancer and cardiovascular diseases, and promoting the overall healthcare system. For instance, France's government launched the France Genomic Medicine Plan 2025. The objective of this plan is to leverage the French healthcare system with closer integration of research, training, and innovation to enhance healthcare services and improve quality of life.
Source: Polaris Market Research Analysis
Multiomics Market Competitive Landscape and Strategic Partnerships
Strategic Partnerships to Drive the Competition
The growing investments in R&D for drug discovery and new technology are positively impacting the global multiomics market. The ongoing expansion initiatives, including partnerships, acquisitions, and collaborations, are fueling competition in the marketplace. For instance, in January 2023, CosmosID launched metabolomics services aiming to expand its multi-omics capabilities.
Leading Companies in the Multiomics Market
- BD
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Danaher (Beckman Coulter)
- PerkinElmer, Inc.
- Shimadzu Corporation
- Bruker
- QIAGEN
- Agilent Technologies, Inc.
- BGI Genomics
Future Outlook for the Multiomics Market
Multiomics market is expected to grow at a steady pace owing to the expansion of precision healthcare and advanced molecular research. Increasing application of multiomics in cancer research, rare disease research and drug discovery will drive the demand. Advancements in sequencing technology, single cell omics and data analysis will make multiomics more efficient and accessible. With continuous research, multiomics is expected to have an increasing role in healthcare and life sciences.
Recent Developments
- June 2026: Illumina launched its StrataMap Spatial Solution for spatial transcriptomics, integrating transcriptomic, genomic, epigenomic, and proteomic data on a single platform to advance disease research and precision medicine.(Source: www.illumina.com)
- January 2026: Illumina introduced Illumina Connected Multiomics, a cloud-based platform for multiomics data analysis. It brings different omics data together and uses AI to make analysis faster and simpler. (Source: investor.illumina.com)
- In June 2025: Bruker acquired Austria-based Biocrates, a specialist in mass spectrometry-driven quantitative metabolomics, to broaden its clinical and translational research capabilities across Europe and global markets. The acquisition reinforces Bruker’s role in precision medicine, expands its metabolomics portfolio, and supports biomarker discovery, diagnostics advancement, and systems biology research worldwide.
- In May 2025: Illumina released DRAGEN v4.4, strengthening clinical oncology and multiomics research capabilities. The update introduces enhanced algorithms for better variant detection and improved data analysis efficiency. It also enables expanded somatic and germline workflows, speeds up whole-genome processing, and delivers greater accuracy in detecting low-frequency variants across diverse datasets.
- In January 2024: Akoya Biosciences and Thermo Fisher Scientific announced a license & distribution agreement to deliver spatial multi-omics solutions.
Report Coverage
The Multiomics Market report emphasizes key regions across the globe to provide a better understanding of the product to the users. Also, the report provides market insights into recent developments and trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers an in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides a detailed analysis of the market while focusing on various key aspects such as competitive analysis, product & services, type, platform, application, end-user, and their futuristic growth opportunities.
Report Scope
| Report Attributes | Details |
| Market size value in 2025 | USD 3.20 Billion |
| Market size value in 2026 | USD 3.68 Billion |
| Revenue Forecast in 2034 | USD 11.53 Billion |
| CAGR | 15.30% from 2026 – 2034 |
| Base year | 2025 |
| Historical data | 2021 – 2024 |
| Forecast period | 2026 – 2034 |
| Quantitative Units | Revenue in USD million and CAGR from 2026 to 2034 |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Multiomics Market FAQ's
The global Multiomics Market size was valued at USD 3.20 Billion in 2025 and is projected to grow to USD 11.53 Billion by 2034.
The global market is projected to grow at a CAGR of 15.30% during the forecast period, 2026-2034.
North America had the largest share of the global market.
The key players in the market are BD (U.S), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Danaher (Beckman Coulter) (U.S.), PerkinElmer, Inc. (U.S.), Shimadzu Corporation (Japan), Bruker (U.S.), QIAGEN (Germany), Agilent Technologies, Inc. (U.S.), and BGI Genomics (China).
The Single-cell multi-omics segment category held the highest share of the market in 2025.
The metabolomics segment is expected to witness the highest growth during the forecast period
Multiomics combines different types of biological data in one study. It gives a better understanding of health and disease.
It analyzes DNA, RNA, proteins and other molecules together. The combined data provides a more complete picture of biological processes.
Common omics technologies are genomics, transcriptomics, proteomics, metabolomics and epigenomics. They study different biological layers.
Multiomics gives a better understanding of each patient's condition. This helps in selecting more suitable treatments.
Download Sample Report of Multiomics Market
Please fill out the form to request a customized copy of the research report.
